Growth and Challenges in the Hospital-Acquired Infection Treatment Market
Hospital-acquired infections (HAIs), also known as nosocomial infections, have emerged as a significant challenge for the medical and healthcare sectors, imposing not only physical discomfort and anxiety but also substantial economic burdens. Recent data reveals the staggering impact of HAIs on hospitals, patients, their families, community services, and the healthcare industry as a whole.
Economic Strain on Hospitals
During the 1990s, the national burden of HAIs occurring in surgical patients in England was estimated to exceed £170 million, exclusively in the hospital sector. These infections persistently strain healthcare resources and continue to be a major concern.
Rising Costs and Demand
Multiple studies have highlighted the direct economic burden of HAIs to be approximately US$10 billion on the healthcare system, with an annual societal cost surpassing US$200 billion. Experts predict that the number of healthcare-associated infections will reach over 2 million annually by 2025, driven by the increasing number of hospital admissions and outpatient visits.
Factors Fueling the Problem
The rise in surgical procedures, expanding geriatric populations with weakened immune systems, poor healthcare administration in middle- and low-income countries, and the growing threat of antibiotic resistance all contribute to the escalating issue of HAIs. Environmental factors such as bacterial presence in hospitals, high humidity, and high temperatures also play a significant role in driving the prevalence of these infections.
Mucormycosis in COVID-19 Survivors
The recent surge in COVID-19 cases in India has brought another alarming concern – mucormycosis, or black fungus, is affecting COVID-19 survivors. Extended use of steroids and immunosuppressant medications, especially among patients with pre-existing comorbidities, puts them at maximum risk. Hospitals in India have reported a significant increase in mucormycosis cases among COVID-19 patients.
Urinary tract infections (UTIs) remain the most commonly seen types of HAIs, along with lower respiratory tract infections (LRTIs) and surgical wound infections (SWIs). UTIs and SWIs alone contribute to 50% of HAI cases, with urinary catheters associated with nearly 75% of UTIs.
Antibacterial Treatment Dominates
The hospital-acquired infection treatment market is dominated by antibacterial treatments, given the prevalence of bacterial infections in healthcare settings. Alarming statistics from the World Health Organization (WHO) indicate a significant increase in antibiotic consumption, raising concerns about antibiotic resistance becoming a leading cause of death.
Asia Pacific Market Growth
The Asia Pacific region is expected to witness substantial growth in the hospital-acquired infections market, driven by poorly maintained hygiene in healthcare settings, government initiatives to increase awareness, rising hospital admissions, and an increasing incidence of chronic diseases. The recent surge in mucormycosis cases during the second wave of the global COVID-19 pandemic presents both challenges and untapped opportunities in this market.
Key Market Players
Prominent companies driving the competition in the global hospital-acquired infection treatment market include Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company Limited, AbbVie Inc., F. Hoffmann-La Roche Ltd, Allergan Plc., Bristol-Myers Squibb, AstraZeneca, Cepheid, Johnson & Johnson Services, Inc., Cipla Inc., DAIICHI SANKYO COMPANY LIMITED, GlaxoSmithKline plc., and Eli Lilly and Company.
The economic burden of hospital-acquired infections remains a pressing concern, underscoring the need for continued efforts in infection control and treatment.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 – By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/hospital-acquired-infection-treatment-market
Visit Our Blogs:
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
This press release first seen on Brilad